A fusion protein derived from Moraxella catarrhalis and Neisseria meningitidis aimed for immune modulation of human B cells.
Mukherjee, Oindrilla LU ; Singh, Birendra LU ; Bayrak, Burcu LU ; Jonsson, Ann-Beth ; Mörgelin, Matthias LU and Riesbeck, Kristian LU
(2015)
In Human Vaccines & Immunotherapeutics
11(9).
p.2223-2227
- Abstract
- Moraxella IgD-binding protein (MID) is a well characterized trimeric autotransporter that specifically targets the IgD of B cells. We fused the membrane anchor of the meningococcal autotransporter NhhA with the IgD-binding region of MID (aa 962-1200) to create a chimeric protein designated as NID. The aim was to use this specific targeting to provide a better vaccine candidate against meningococci, in particular serogroup B by enhancing the immunogenicity of NhhA. NID was thereafter recombinantly expressed in E. coli. The NID-expressing E. coli bound to peripheral B lymphocytes that resulted in cellular activation. Furthermore, we also successfully expressed NID on outer membrane vesicles, nanoparticles that are commonly used in... (More)
- Moraxella IgD-binding protein (MID) is a well characterized trimeric autotransporter that specifically targets the IgD of B cells. We fused the membrane anchor of the meningococcal autotransporter NhhA with the IgD-binding region of MID (aa 962-1200) to create a chimeric protein designated as NID. The aim was to use this specific targeting to provide a better vaccine candidate against meningococci, in particular serogroup B by enhancing the immunogenicity of NhhA. NID was thereafter recombinantly expressed in E. coli. The NID-expressing E. coli bound to peripheral B lymphocytes that resulted in cellular activation. Furthermore, we also successfully expressed NID on outer membrane vesicles, nanoparticles that are commonly used in meningococcal vaccines. This study thus highlights the applicability of the menigococcal-Moraxella fusion protein NID to be used for specific targeting of vaccine components to the IgD B cell receptor. (Less)
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/7488240
- author
- Mukherjee, Oindrilla
LU
; Singh, Birendra
LU
; Bayrak, Burcu
LU
; Jonsson, Ann-Beth
; Mörgelin, Matthias
LU
and Riesbeck, Kristian
LU
- organization
- publishing date
- 2015
- type
- Contribution to journal
- publication status
- published
- subject
- in
- Human Vaccines & Immunotherapeutics
- volume
- 11
- issue
- 9
- pages
- 2223 - 2227
- publisher
- Taylor & Francis
- external identifiers
-
- pmid:26042357
- wos:000360493900024
- scopus:84954563915
- pmid:26042357
- ISSN
- 2164-5515
- DOI
- 10.1080/21645515.2015.1034917
- language
- English
- LU publication?
- yes
- id
- 10e18ea2-7637-4f32-b23c-dca89228d5d3 (old id 7488240)
- alternative location
- http://www.ncbi.nlm.nih.gov/pubmed/26042357?dopt=Abstract
- date added to LUP
- 2016-04-01 10:29:01
- date last changed
- 2022-04-12 06:50:19
@article{10e18ea2-7637-4f32-b23c-dca89228d5d3,
abstract = {{Moraxella IgD-binding protein (MID) is a well characterized trimeric autotransporter that specifically targets the IgD of B cells. We fused the membrane anchor of the meningococcal autotransporter NhhA with the IgD-binding region of MID (aa 962-1200) to create a chimeric protein designated as NID. The aim was to use this specific targeting to provide a better vaccine candidate against meningococci, in particular serogroup B by enhancing the immunogenicity of NhhA. NID was thereafter recombinantly expressed in E. coli. The NID-expressing E. coli bound to peripheral B lymphocytes that resulted in cellular activation. Furthermore, we also successfully expressed NID on outer membrane vesicles, nanoparticles that are commonly used in meningococcal vaccines. This study thus highlights the applicability of the menigococcal-Moraxella fusion protein NID to be used for specific targeting of vaccine components to the IgD B cell receptor.}},
author = {{Mukherjee, Oindrilla and Singh, Birendra and Bayrak, Burcu and Jonsson, Ann-Beth and Mörgelin, Matthias and Riesbeck, Kristian}},
issn = {{2164-5515}},
language = {{eng}},
number = {{9}},
pages = {{2223--2227}},
publisher = {{Taylor & Francis}},
series = {{Human Vaccines & Immunotherapeutics}},
title = {{A fusion protein derived from Moraxella catarrhalis and Neisseria meningitidis aimed for immune modulation of human B cells.}},
url = {{https://lup.lub.lu.se/search/files/1878990/8564668.pdf}},
doi = {{10.1080/21645515.2015.1034917}},
volume = {{11}},
year = {{2015}},
}